Fusion Pharmaceuticals
Targeted alpha therapeutics (TAT) for the treatment of chemotherapy resistant cancers. Learn more
Launch date
Employees
Market cap
€1.7b
Enterprise valuation
€1.5b (Public information from May 2024)
Share price
$21.55 FUSN
Hamilton Ontario (HQ)
Authorizing premium user...